pd initi outperform
initi coverag voyag therapeut outperform rate
price target base view signific commerci potenti parkinson
diseas pd gene therapi vy-aadc evalu clinic program
pd expect pd gene therapi potenti signific advantag deep
brain stimul db current market target consid
similar patient popul estim po pivot
trial believ potenti disrupt db market attract pd
patient earlier onset diseas may offer superior efficaci conveni
done option vs routin follow-up mainten requir
aav gene therapi compani focu neurolog diseas
vygr pipelin includ one clinic stage asset vy-aadc pivot
trial parkinson diseas asset preclin develop
invest thesi base estim vy-aadc probabl success
pivot trial commerci uptak vy-aadc pd
current treatment option advanc pd includ db surgeri involv
implant electron devic brain db becom standard
care soc advanc pd db surgeri perform
us annual believ gene therapi may potenti disrupt db market
help advanc pd patient previous consid db
db devic first approv fda soc sinc
approxim annual world-wide sale market domin
despit fact db devic cost
surgeri implant devic maintenance-associ cost may averag
subsequ five-year period
believ gene therapi approv may favor option vs db
patient suffer advanc pd advantag gene therapi may
includ motor function improv reduc levodopa uptak less follow-up
uniqu aav-deliv aadc gene therapi pivot clinic
studi partner anoth leader neurosci
estim probabl success po pivot studi
forecast unrisk-adjust peak revenu
vy-aadc pd indic pt outperform rate
base dcf valuat methodolog driven risk-adjust sale vy-
aadc subsequ gradual declin
year price histori
clinical-stag gene
compani develop treatment
patient suffer central nervou
system disord pipelin gene
tau compani
found headquart
analyst certif import disclosur see disclosur
outperform rate base belief
share under-valued accord evalu
compani main asset vy-aadc registr
advanc parkinson diseas patient
current advanc parkinson diseas patient may
candid deep brain stimul surgeri rel
small number patient typic pursu procedur
believ vy-aadc well posit offer addit
option advanc parkinson diseas patient given
uniqu combin aav deliveri aadc-target gene
activ vy-aadc demonstr registr trial
period updat trial
initi trial
updat preclin program
result trial result
trial
result observ extens studi
enrol registr trial
initi registr trial
ind file initi huntington diseas
posit differenti vy-aadc activ
advanc pipelin asset
acquisit signific premium
financ greater
restor
expect
vy-aadc activ restor trial disappoint result
restor clinic trial take longer expect and/or
competit landscap parkinson diseas limit vy-aadc
price target base dcf valuat methodolog assum wacc residu
growth rate anticip launch vy-aadc peak sale patent expir forecast ww
risk-adjust vy-aadc sale driven vy-aadc parkinson diseas indic probabl success vy-
aadc parkinson diseas indic
key downsid risk price target clinic develop regulatori risk vy-aadc addit risk includ build
commerci infrastructur parkinson diseas indic higher anticip competit parkinson diseas therapi
upsid risk includ acquisit signific premium better expect clinic data vy-aadc
initi coverag outperform
rate price target base view signific commerci potenti
compani main asset vy-aadc evalu pivot clinic trial
parkinson diseas pd patient price target repres potenti upsid
current trade level
aav gene therapi compani focu neurolog diseas
pipelin includ one clinic asset vy-aadc current pivot trial pd
asset preclin develop
invest thesi base understand vy-aadc probabl success
pivot trial potenti commerci uptak vy-aadc pd
current treatment regimen advanc pd includ deep brain stimul db
surgeri involv implant electr devic electrod brain tissu
help reduc pd-associ clinic manifest tremor dyskinesia
estim pd patient us approxim
advanc stage db standard care advanc pd
surgeri perform us annual believ gene therapi solut
may potenti disrupt db market help advanc pd patient previous
consid db
db devic first approv us year ago estim
annual world-wide db devic sale captur three major player
market abbott
despit fact db devic cost surgeri implant
devic maintenance-associ cost may averag subsequ five-
believ gene therapi approv may becom prefer choic vs db
patient suffer advanc pd advantag gene therapi may includ
improv motor function reduc levodopa uptak absenc mainten
associ db devic
uniqu aav-deliv aadc gene therapi pivot clinic studi
partner anoth leader neurosci
estim probabl success po pivot studi
potenti fda approv launch lead un-risk-
adjust revenu vy-aadc pd indic
price target base dcf valuat
methodolog assum weight averag cost capit wacc
residu growth rate view appropri given
access collabor capit via agreement partner vy-aadc multipl
patent expir expect possibl late end
cash cash equival addit gross shelf
registr equiti financ announc novemb vygr current market
capit around base basic share base potenti
includ vygr pre-clin candid valuat analysi re-
assess contribut vygr valuat if/when asset move clinic
assum probabl success vy-aadc secur fda/ema approv
advanc pd patient addit assum variou market penetr percentag
pd popul group
penetr current incid db market everi year around
american make decis implant db devic believ vy-
aadc may potenti abl captur market
penetr current preval db market estim
around american current wear db devic vy-
aadc may potenti abl switch advanc pd patient
gene therapi solut
penetr advanc pd market patient
previous consid db treatment due inconveni devic
mainten need etc estim around american
advanc pd vy-aadc may potenti abl help
ex-u row revenu assum multipl factor consist
ex-u proport sale major db manufactur
key downsid risk price target includ clinic develop risk vy-aadc
registr trial advanc pd patient addit risk come
build commerci infrastructur support pd indic post-regulatori approv
grant lower expect sale due higher anticip
competit failur gain support physician commun us/ex-u payer
may requir signific addit fund pre-launch commerci oper
form dilut equiti
key upsid risk price target includ acquisit signific premium
current share price better expect clinic data see small-cap gene therapi
compani potenti acquisit target larg biopharma compani
upcom catalyst includ pd-relat updat three-year result
trial two-year result trial
catalyst may also includ initi result extens studi
updat enrol registr trial
also expect initi registr trial
preclin pipelin side expect ind file initi
huntington diseas trial may affect model may consid
includ huntington diseas potenti revenu driver
also could updat preclin program current
expect updat significantli impact valuat thesi
yet announc particip major neurolog confer
suspect updat happen sever confer throughout cours
exhibit catalyst calendar
histori stock price ownership
vygr stock price ltm vs
nbi current institut ownership septemb repres
stock top institut investor includ bellevu asset manag
clearbridg invest casdin capit other
insider/stakehold stock owner includ third ventur
exhibit top institut top insiders/stakehold septemb
stock price movement past two year impli stock appreci driver
may includ collabor agreement variou partner result immedi
potenti collabor revenu serv valid point vygr aav platform
factset oppenheim co note result view indic futur result
file registr statement base prospectu cover
potenti offer vygr secur registr statement also
includ sale agreement prospectu offer vygr common stock may
issu follow-on offer
later file prospectu util shelf registr process potenti
common stock offer may use gener corpor purpos
think vygr financ decis may readi measur prepar
financ new clinic trial collabor capit readili access
clinical-stag gene therapi compani focus develop treatment
sever neurolog diseas compani special adeno-associ viru
aav gene therapi approach may increase/decreas product specif
protein potenti slow clinic symptom experienc patient
appear lead compani intersect aav gene therapi
neurolog diseas aav platform may leverag engin optim
deliv aav-bas gene therapi potenti durabl efficaci follow singl
protein shell enclos genet materi viru payload typic
develop process usual start identifi sever neurolog diseas
potenti aav vector deliv viru payload target tissu
vygr manufactur process may enabl product high qualiti aav vector
commerci scale also work establish innov rout administr
dose techniqu optim deliveri aav gene therapi target tissu
target infus discret region brain spinal cord conjunct
tout aav deliveri target pathway broadli applic scalabl valid
safe durabl
vygr busi strategi includ in-licens gene therapi program certain
research institut collabor larg pharma partner develop gene
therapi product vygr current partner includ neurocrin
vygr advanc clinic candid vy-aadc pd partner
parkinson diseas pd affect estim american men women though
slightli common men pd caus combin genet
environment factor age main risk factor cure
multipl symptomat treatment medic exercis nutrit surgic treatment
potenti reduc symptom improv qualiti life
common symptom pd includ tremor bradykinesia muscl rigid postur
instabilityal refer motor symptom pd also non-motor
symptom includ depress anxieti apathi fatigu sexual dysfunct
initi stage pd within first sever year diagnosi medic
levodopa usual control symptom major patient diseas
progress pd patient may need take medic increas
diseas durat increas peopl pd may notic throughout typic day
experi period adequ symptom control time period
symptom much notic time period peak medic
level usual hour take medic dose produc involuntari movement
dyskinesia patient chang one three state anoth
said motor fluctuat
pd patient advanc stage may opt surgic treatment involv deep
modern db develop franc culmin mani decad
research studi variou brain function advanc technolog surgic
practic therapi continu improv first db devic
approv fda currenti db surgeri consid safe effect
treatment elig advanc pd patient howev patient fulli benefit
procedur advanc pd patient may feel insignific improv
motor function
db involv surgic placement thin wire electr contact lead
specif brain region lead place variou part brain globu
pallidu internu thalamu subthalam nucleu
db lead connect pacemaker-lik devic implant chest
region collarbon db therapi includ implant puls gener
contain batteri comput sourc gener electr puls
deliv via lead brain system turn patient
physician moreov neuorolgist may select electrod brain lead
activ provid electr stimul process allow electr stimul
deliv specif part brain
db specialist adjust varieti electr paramet set control
amount stimul provid allow physician maxim benefit
minim side effect
wide believ physician commun db help reliev
symptom pd cure stop diseas progress
db surgeri associ cost
db procedur refer neurosurgeon neuorlogist treat pd patient
surgeri perform hightli special stereotact surgeon db
surgeri may cost depend specif procedur cost includ
price surgeri db devic anesthesia hospit physician fee
db devic may cost depend brand model devic
exhibit exampl db devic bill price pd
howev five-year period cost db surgeri averag
three major competitor db marketmedtron abbott boston
scientifc largest market share first compani whose devic
approv back claim patient
implant db devic sinc
base publish data accord interview db kol estim
db surgeri accordingli db revenu book
manufactur relat parkinson diseas
exhibit approxim db surgeri distribut diseas
medtron db system domin market db therapi usual
easili reimburs medicar accord kol current approv mani
locat around world signifc intern presenc
leverag facilit sale mainten db devic around globe
db busi year estim compani
gener revenu devic also associ
maintenance-rel accessori batteri lead gener etc
exhibit exampl db accessori reimburs price medicar
medtron report db revenu brain therapi segment current
annual run rate assum brain therapi sale refer db
devic accessori relat parkinson disesas
medtron brain therapi segment consistenli grow past two year
annual growth due improv technolog advanc devic
surgeri mri-control
provid split us vs ex-u sale segment overal
compani us sale constitut across segment
elig db devic includ pd diagnosi least four year
movement symptom least four month current respons levodopa
movement symptom control medic
although minimum requir db devic four year sinc initi
diagnosi pd base publish literatur kol consult averag time
sinc intial diagnosi pd diseas db patient decid receiv db
treatment usual year
think late start db surgeri explain reluct patient
wear implant devic attach lead well frustrat associ
mainten devic
abbott report db sale neuromodul segment show split
us vs ex-u sale segment
also report sale neuromodul segment report
us vs ex-u split report split abbott neuromodul
overal across segment us vs ex-u split boston scientif sale
consist abbott
total db market difficult estim partial compani report
db sale separ
combin annual sale brain therapi
neuromodul around assum brain
therapies/neuromodul sale actual db db sale
pd db sale us estim us db
market around annual revenu
hand base publish data approxim db
surgeri perform us everi year consid cost db devic
associ accessori would give similar numberapproxim sale
us
mention previous sale book db manufactur
fraction payer includ medicar pay db procedur
cumul singl db procedur cost averag five-year post-
vygr lead clinic pd candid vy-aadc studi pivot
clinic trial potenti initi readout anoth registr trial
vy-aadc plan initi
pd character loss dopamin function dopamin chemic
courier creat brain tissu involv control motor function
dopamin produc brain enzym aadc aromat l-amino acid
decarboxylas convert levodopa dopamin levodopa dopamin aadc
believ present normal level healthi peopl
dopamin level decreas brain motor symptom pd tremor
slow movement rigid postur instabl may manifest motor
symptom neurologist may prescrib levodopa medic convert
dopamin aadc similar natur happen levodopa
convert dopamin
pd worsen less aadc enzym convert levodopa dopamin
consequ amount dopamin produc dose levodopa may
reduc result motor function may worsen less predict
respons levodopa medic
exhibit vy-aadc aim restor aadc enzym activ
vygr vy-aadc design inject aadc enzym brain cell
convert levodopa dopamin aadc gene deliv insid aav vector so-
preclin studi conduct dr krystof bankiewicz one co-found
team ucsf dr bankiewicz team deliv vy-aadc similar
putamen non-human primat well-toler seriou toxic
moreov pet imag aadc-specif tracer show sustain increas
activ brain region vector deliv also support
behavior improv observ post-treat gene therapi compar pre-
consist pet signal detect five anim follow treatment confirm
deliveri aadc putamen anim significantli sensit levodopa
six month follow treatment gene therapi compar baselin
exhibit behavior respons levodopa pre- post-treat non-human primat
previou trial vy-aadc
updr unifi parkinson diseas rate scale standard four-part clinic rate
scale pd measur cognit function motor deficit medication-
relat complic updr part measur motor function physician examin
updr conduct patient medic patient
medic addit patient-complet so-cal hauser diari record
patient motor respons cours sever day time
time decreas time dyskinesia increas patient progress
earli honeymoon period later stage pd
exhibit pd progress vygr approach
open-label ten-pati trial conduct ucsf vy-aadc deliv directli
putamen pd patient primari endpoint safeti toler met
vy-aadc well-toler report trae
six month follow treatment diari time reduc hour
correspond time without dyskinesia increas also six month follow
treatment improv updr total score on-med
three patient experienc minor hemorrhag relat surgeri result
stereotact inject protocol modifi avoid specif blood vessel
subsequ surgic procedur use real-tim intra-op mri guidanc
consid meaning advanc vector deliveri
ten patient trial follow four year treatment
durabl dose-depend express aadc enzym activ observ patient
show increas pet signal well consid indic aadc
novemb complet enrol open-label dose-escal
patient vy-aadc
exhibit improv time primari endpoint reduct time month
preliminari data trial demonstr vy-aadc well-toler
administr vy-aadc improv patient motor function qualiti life
measur standard score measur use pd trial
exhibit increas aadc enzym activ demonstr pet imag trial
separ clinic trial chang trajectori administr
vy-aadc posterior approach putamen compar transfront deliveri
approach use previou trial
posterior approach may potenti better align infus vy-aadc
anatom structur putamen reduc number trajectori need
potenti reduc total procedur time increas total coverag
administr vy-aadc posterior approach well-toler eight
patient treat report trae patient discharg hospit
day surgeri
administr vy-aadc posterior trajectori result mean coverag
putamen reduc infus time approxim two hour
hour hour compar treatment vy-aadc
increas mean aadc enzym activ putamen measur pet imag
aadc enzym activ putamen reflect capac neuron
brain convert levodopa dopamin
treatment vy-aadc improv patient motor function baselin
diari time includ good time updr activ daili live
measur addit improv patient motor function achiev
mean reduct pd medic dosag levodopa equival baselin
level mg/day measur six month
addit motor function vy-aadc improv patient qualiti life measur
patient-report pd questionnair infus vy-aadc well-toler
eight patient treat sae report
decemb submit ind vy-aadc part ind
chemistri manufactur section includ data demonstr compar
vy-aadc use manufactur process vy-aadc produc
use mammalian cell system consist triple-transfect cell
use two trial
manufactur process design product aav
vector clinic commerci scale potenti increas yield
effici scalabl compar mammalian-bas system use vy-aadc
manufactur system global trial
june fda grant rmat design vy-aadc gene therapi treatment
potenti provid enhanc level interact
fda design base trial data previous fda also grant fast-
track design vy-aadc may make vy-aadc elig acceler
approv prioriti review roll review
decemb enrol first patient random
double-blind placebo-surgeri control trial evalu safeti efficaci vy-
aadc pd diseas patient motor fluctuat refractori medic
manag studi enrol patient diagnos
pd least four year respond adequ oral medic
least three hour time day measur valid self-
report patient diari random expect administr vy-
aadc total dose vg placebo surgeri
primari endpoint good time measur month
secondari endpoint includ diari time updrs-ii updrs-iii score
assess pd questionnair patient global function measur
proport particip improv clinic global impress score
also measur non-motor symptom non-motor symptom scale
safeti
exhibit design registr trial
biomark data includ measur coverag putamen measur
aadc enzym express activ putamen measur pet imag use
fluorodopa chang patient daili dose oral levodopa relat
medic also record
decemb type meet fda result revis
trial protocol increas target number patient trial
result total patient trial plan conduct staggered-parallel
trial similar size design
total patient enrol take month first patient enrol
trial plan begin enrol trial
expect posit result plan
trial could potenti form basi bla submiss fda
march enter collabor agreement research
develop commerci certain aav gene therapi asset includ
pd program fa friedreich ataxia program two program yet
june conjunct termin sanofi collabor agreement
gain ex-u right fa program subsequ
transfer
summari agreement relat pd
base agreement assum respons develop
commerci activ pd fa two program pay mileston
base transit event royalti futur net sale
key transit event respect pd receipt top-line data restore-
program option co-develop co-commerci
result profit loss share arrang vy-aadc upon occurr
specifi event
exchang choos share option would forfeit certain mileston
royalti net sale us
initi paid up-front fee made equiti invest
also entitl reimburs cost incur regard four
develop program prior transit event
estim total variabl cost reimburs across nbix-rel program
variabl cost reimburs relat pd
exhibit reimburs
accord agreement regard pd
agre
howev may elect within specifi period follow accept bla
pay rate-shift fee chang alloc pd program
purpos model vygr futur assum base profit-
maxim principl support game theori choos option co-
commerci vy-aadc turn choos pay rate-shift
fee alloc
howev assumpt may chang subsequ period may see
success potenti clinic program huntington diseas
gene therapi competit pd
besid special aav deliv gene therapi neurodegen
diseas multipl gene therapi compani includ axov prevail
seelo potenti competitor space
axov market cap clinical-stag compani focus develop
gene therapi neurolog diseas
current axo-lenti-pd gene therapi candid pd program
develop compris first gener prosavin patient
previous dose studi second gener axo-lenti-pd
six year data patient dose phase clinic trial prosavin
data two patient dose cohort phase clinic trial
sunrise-pd studi expect initi data six patient dose cohort
sunrise-pd studi
axo-lenti-pd deliv construct three gene encod enzym believ
requir biochem synthesi dopamin endogen tyrosin
enzym tyrosin hydroxylas th enzym convert tyrosin
levodopa cyclohydrolas rate-limit enzym synthesi
tetrahydrobiopterin critic cofactor product levodopa aadc axo-
lenti-pd deliv one-tim stereotact guid infus putamen
prevail market cap compani focus aav-bas
appli precis medicin approach neurodegener explor gene
therapi genet defin patient popul believ precis
medicin would increas probabl success creat disease-modifi
prvl lead program treatment pd mutat pd-gba
design target us pd patient american
seelo seel market cap compani focus primarili
develop acquisit clinical-stag therapeut candid
seel pd candid preclin stage develop
market cap commercial-stag compani focus
discoveri develop commerci rare diseas
gene therapi product candid ptc-aadc treatment aadc
defici submit ptc-aadc applic europ prepar
bla submiss fda ptc-aadc us expect
exhibit pipelin updat januari
aadc defici monogen disord neurotransmitt synthesi manifest
young children result signific development delay often seen complet
dysfunct motor develop
aadc defici caus inabl develop motor control result breath
feed swallow problem frequent hospit need life-long
care patient aadc defici may die first ten year life due deep motor
dysfunct secondari complic choke hypoxia pneumonia
treatment option avail underli caus aadc defici
care limit palli option subsequ burden caregiv
preval aadc defici estim approxim patient
world-wide accord
ptc-aadc aav gene therapi assess two complet clinic trial
patient
trial ptc-aadc surgic deliv putamen result
trial suggest patient may gain motor function improv
cognit scale follow ptc-aadc administr show signific increas
motor function compar posit publish natur histori
believ certain similar ptc-aadc vy-aadc term
mechan action aav deliveri surgic intervent regulatori pathway
aadc defici orphan diseas impli acceler regulatori
pathway think possibl approv ptc-aadc may serv valid
provid support vy-aadc clinic develop
model vy-aadc db candid
order realist estim potenti sale vy-aadc pd indic
analyz consid compar market pd db market
previous mention assum current us db market around
surgeri per year averag price per surgeri plu five-year follow around
believ vygr gene therapi solut may signific advantag
current db therapi vy-aadc cure believ may effici
conveni approach reduc pd symptom
think reason assum price entri point around
singl administr given absenc mainten visit program
think three market segment vy-aadc may attempt break
patient consid undergo db surgeri incid patient
current db patient implant db devic
pd patient previous consid db surgeri may attract
newli approv gene therapi solut
also assum split rest world row factor consist
row factor abbott revenu db
also assum po current registr stage clinic
develop appropri histor compar precis
estim po howev believ po number rel conserv
lower bound number usual assign po late stage non-gen
therapi asset base histor preced
first group db incid patient think penetr
db treatment gradual lose market share gene therapi
final estim un-risk-adjust sale patient sub-popul
model vy-aadc current db
second group patient model current db patient estim
db pd patient us
estim base partial report db devic implant
sinc assum db devic pd abbott boston
scientif also market share assum pd patient us
implant db devic
total sale vy-aadc parkinson sale sale sale price launch singl time us gross-to-net discount price current parkinson diseas db candid patient popul yoy growth preval pd patient patient plan undergo db plan undergo db market share vy-aadc potenti db price yoy growth discount vy-aadc pd patient db candid risk adj net sale row parkinson diseas db candid patient row sale risk adj net sale voyag therapeut
howev current db patient late stage pd may multipl
comorbid addit psychot symptom dementia mani
patient would probabl elig gene therapi surgeri
assum penetr sub-popul pd patient due rather
late stage diseas forecast un-risk-adjust revenu patient
model vy-aadc futur db
largest pool potenti patient may come current advanc pd patient
consid db surgeri due challeng associ wear
implant devic mainten care devic inconveni etc
estim advanc us pd patient total pd
popul hypothet benefit vy-aadc potenti
current enrol criteria registr trial includ diseas durat
diagnosi greater equal four year diseas durat criteria
similar db devic think patient physician might
will accept new therapi defer db later line therapi
forecast penetr pd popul group potenti un-risk-
adjust sale
launchu parkinson diseas current db patient popul yoy growth preval pd patient preval pd patient current pd patient current db market share vy-aadc db current price yoy growth discount vy-aadc pd patient currenlti db adj net sale parkinson diseas current db patient row sale adj net sale outperform
number preclinical-stag asset huntington
diseas monogen al friedreich ataxia tau
alpha-synuclein program preclin program partner
sponsor larg biopharmaceut compani
howev valuat purpos includ preclin candid
model appropri establish either potenti sale probabl
success indic drug candid time
launchu parkinson diseas yr consid db popul yoy growth preval pd patient preval pd patient yr consid pd patient yr consid db market share vy-aadc consid db price yoy growth discount vy-aadc pd patient yr consid db adj net sale parkinson diseas yr consid row sale adj net sale voyag therapeut
appear patent pend applic file
behalf univers grant exclus right technolog
protect invent associ aav-bas biolog
accord sec file patent applic pend
us world-wide cover aav technolog biolog product
patent issu licensor grant exclus
licens right technolog covered/pat intellectu properti right includ
method transfer genet materi cell method design novel aav
construct aav-bas biolog product method treat diseas interest
method manufactur aav-bas product
parkinson diseas relat technolog patent includ four pend patent famili
one issu patent patent applic direct aav construct encod
gene aadc therapeut use patent gener expect start expir
andr turenn presid chief execut offic
andr turenn serv busi develop commerci leadership role
includ nearli year genzym sanofi recent serv sanofi
senior vice-president global head busi develop licens respons
partner activ across sanofi busi unit includ sanofi pasteur
sanofi genzym diabetes-cardiovascular gener medicin consum health
also serv chair sanofi transact committe previous serv
global head strategi busi develop genzym follow acquisit
sanofi addit busi develop leadership posit mr turenn
held senior leadership posit countri level gener manag sanofi
genzym australia/new zealand respons region global
franchis level head commerci oper renal endocrinolog
divis achiev annual revenu time mr turenn began
career industri consult kendal strategi consult arm
feinstein kean healthcar part ogilvi
positionnamepresid chief execut officerandr turennechief medic offic head domar khwaja ph chief oper officermatthew ottmerchief technic oper officerlui maranga ph chief officerallison dorvalchief busi officerallen nunnal outperform
mr turenn hold ba kalamazoo colleg tuck school
busi dartmouth
omar khwaja ph chief medic offic head
omar khwaja extens research translat clinic therapeut develop
experi neurosci neurogenet rare diseas industri
academ role dr khwaja join roch ag recent serv
global head neurosci translat medicin global head
diseas seven year roch dr khwaja establish integr
discoveri develop rare diseas unit clinic develop neurosci
within group dr khwaja led initi roch first clinic program gene
therapi deliv pivot trial multipl program across variou therapeut
modal indic includ spinal muscular atrophi sma huntington
diseas join roch dr khwaja director clinic neurogenet
program boston children hospit faculti harvard medic school
dr khwaja receiv ph univers cambridg uk
train pediatr clinic genet london uk melbourn australia
complet neurolog train massachusett gener hospit boston
children hospit chief resid member royal colleg
physician unit kingdom member royal colleg paediatr
child health
matthew ottmer year biotechnolog industri experi includ
execut leadership busi oper product develop commerci
across multipl therapeut area stage develop mr ottmer join
recent chief oper offic
respons program allianc manag research clinic develop
pharmaceut scienc commerci activ sinc late prior role
spent year inc varieti leadership role includ svp strategi
emerg busi head tysabri busi chief staff chief execut
offic presid wholli own subsidiari
bioverativ vice-president global oper
mr ottmer receiv ba polit scienc univers michigan
univers kellogg school manag
lui maranga join year biotechnolog industri experi
focus bioprocess develop chemistri manufactur control good
manufactur process gmp process valid regulatori submiss
facil manag includ extens work express
system dr maranga recent serv vice-president biolog develop bm
respons process analyt develop clinic manufactur
post-discoveri commerci launch bmss biolog program
also held previous role gener manag deven biolog commerci
oper site head hopkinton site execut director biolog
manufactur scienc technolog prior bm dr maranga serv head
technic develop viral vaccin novarti held senior role biolog
vaccin astrazeneca/medimmun merck co dr maranga expert
biolog vaccin gene therapi develop manufactur
dr maranga hold ph chemic engin universidad de lisboa
bs chemic engin instituto superior tecnico portug
allison dorval year corpor financ account experi
includ nine year life scienc execut financ experi prior ms
dorval serv recent inc insulet corpor
led financi plan report account previous ms dorval held
corpor financ posit ibasi inc digita inc ms dorval
began career public account pricewaterhousecoop llp held
posit increas respons scope
ms dorval obtain bs busi administr account concentr
univers vermont
allen nunnal scienc career span two decad focus genetically-
genomically-driven technolog medicin organ rang early-stag
biotech fortun pharma compani prior join mr nunnal serv
vice-president corpor busi develop associ gener counsel
foundat medicin led transact relat biopharmaceut busi
comprehens genom profil companion diagnost data product
direct compani intellectu properti strategi mr nunnal repres
foundat medicin seri financ ipo co-l
collabor compon broad strateg transact roch acquir
major interest foundat medicin mr nunnal previous spent year
attorney law firm wilmer cutler picker hale dorr llp
repres wide array lead pharmaceut biotechnolog client
mr nunnal receiv ba doubl major biolog law jurisprud
social thought amherst colleg boston univers school law
concentr intellectu properti law
expect un-risk-adjust sale reach ww driven pd
indic vy-aadc assum probabl success pd indic
assum launch vy-aadc
assum single-administr wac price vy-aadc gross-
to-net customari discount assumpt annual growth us-estim price
line long-term project growth
exhibit forecast
except per share data fy risk-adjust vy-aadc parkinson disease- probabl parkinson diseas risk-adjusted- collabor mileston probabl collabor mileston revenu total revenu goodscogs- gross oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op ex sg total oper expens cog royalti oper incom oper incom relat vy-aadc only- oper incom share relat incom valuat interest total non-oper incom pre-tax incom incom tax benefit expens tax incom net unreal gain available-for-sal total comprehes incom comprehens incom basic share outstand share outstand share outstand ep ep oppenheim co estim compani data
price target base dcf valuat
methodolog assum wacc residu growth rate
anticip launch vy-aadc follow peak sale patent expir
report septemb cash cash equival balanc
forecast ww risk-adjust sale vy-aadc driven pd
indic vy-aadc probabl success vy-aadc pd indic
exhibit dcf valuat except share
voyag fy asset cash market secur collabor receivable- unbil receivable- prepaid expens current total current properti equip deposit non-curr oper leas right-of-us assets- market secur total liabilitiescurr liabil account accru current liabilities- defer revenu current total current defer revenu net current non-curr total total stockhold total liabil sourc oppenheim co compani report voyag
voyag fy incom adjustmentsstock-bas amort premium discount mark in-kind research develop non-cash chang oper asset liabilitiescollabor receivable- unbil receivable- prepaid expens current oper leas right-of-us asset- non-curr assets- account accru oper leas liabil incent defer flow purchas properti proce loss sale equipment- purchas market proce matur market flow proce exercis stock proce issuanc common stock incl proce purchas common stock flow net increas decreas equival without market sourc oppenheim co compani report outperform
probabl success
probabl success
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex sg
oper incom relat vy-aadc
oper incom share
 relat
oper incom valuat purpos
net unreal gain available-for-sal secur
total comprehes incom loss
stock price compani mention report
